Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to monitor the long-term safety and tolerability of tesaglitazar (0.5-1 mg) versus glibenclamide (2.5-15 mg), with or without other oral anti-diabetic drugs, when administered for up to 100 weeks in an extension study from the GALLANT 4 study in patients with type 2 diabetes by evaluation of adverse events (AEs), laboratory variables, physical examination, cardiac evaluation, hypoglycaemic events, electrocardiogram (ECG), vital signs (blood pressure (BP) and pulse), body weight and height
Critère d'inclusion
- type II diabetes mellitus